Fact Source: Financial Supervisory Service DART / 2026-03-17
Disclosure Type: Signing of a Single Sales/Supply Contract
💡 3-Second Summary
Celltrion has entered into a contract manufacturing organization (CMO) agreement worth approximately KRW 294.9 billion with a global pharmaceutical firm, with the potential to increase up to KRW 375.3 billion upon the counterparty’s request.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Contract Name: Pharmaceutical Contract Manufacturing Agreement (Other Sales/Supply Contract)
- Contract Amount: KRW 294,921,000,000 (Approx. KRW 294.9B)
- This represents 8.29% of the company’s recent annual revenue (KRW 3,557,303,554,371 based on the 2024 consolidated financial statements).
- The amount was calculated based on the initial base exchange rate of USD/KRW 1,489.50 as of March 16, 2026.
- The contract value may increase up to KRW 375,354,000,000 (Approx. KRW 375.3B) depending on the counterparty’s requirements.
- Contract Counterparty: A global pharmaceutical company (Confidential until December 31, 2029, due to business confidentiality requests)
- Contract Period: March 16, 2026 – December 31, 2029
- Actual supply is scheduled to commence starting from Q1 2027.
- Key Contract Conditions: No down payment or advance payment is involved.
- Contract/Order Date: March 16, 2026
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This contract represents a significant development that proves substantial growth in Celltrion’s contract manufacturing (CMO) business, serving as a solid indicator of fundamental strength. Since the initial contract value accounts for 8.29% of recent annual sales and could potentially scale up to KRW 375.3 billion, it is likely to have a meaningful positive impact on medium-to-long term revenue expansion.
Investors should pay close attention to the fact that actual shipments are scheduled to begin in Q1 2027. This timeline implies that the financial contributions from this deal will start reflecting in Celltrion’s earnings from fiscal year 2027, making it more appropriate to evaluate this as a structural long-term revenue stream rather than an immediate catalyst for short-term earnings. While the counterparty name and specific supply regions are temporarily withheld under a confidentiality agreement until December 31, 2029, tracking subsequent disclosures for any early lifting of the non-disclosure terms will be helpful to evaluate the broader scope of Celltrion’s global partnerships.
📝 Editor’s Comment (by K-STOCK Editor)
Celltrion has once again demonstrated its manufacturing competitiveness by securing a high-value CMO deal from an unnamed global pharmaceutical company. Representing over 8% of annual sales with room for further expansion, this agreement serves as a favorable signal for the diversification of its business model beyond biosimilar development. Given that physical product deliveries are scheduled to begin in Q1 2027, this development should be viewed as a long-term fundamental builder reinforcing steady future cash flows, rather than a driver of immediate market speculation.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
